TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03560193
Drug: 5%Povidone Iodine- 69%Ethanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5%Povidone Iodine- 69%Ethanol will be used to disinfect the skin before Cardiac Surgery and during all dressing changes
Study: NCT02039180
Drug: AZD3293 oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive AZD3293 as a tablet (Formulation A; Formulation B) and solution as a single dose on Day 1, Day 8 or Day 15.
Study: NCT02039180
Drug: AZD3293 tablet formulation B
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive AZD3293 as a tablet (Formulation A; Formulation B) and a solution as a single dose on Day 1, Day 8 or Day 15.
Study: NCT00816907
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 to 2 placebo capsules taken twice daily for 16 weeks
Study: NCT02040194
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel for intratympanic injection
Study: NCT00633438
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg oral capsule as single dose administered 1 hour prior to surgery and 200 mg oral capsule as single dose administered post surgery as needed
Study: NCT00016523
Drug: Inhaled nitric oxide
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Started at 5 ppm and could be increased to 10 ppm
Study: NCT00016523
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Started at 5 ppm and could be increased to 10 ppm
Study: NCT02571192
Drug: SHP626
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose 50mg SHP626 with approximately 5.95 μCi RAD
Study: NCT01665417
Drug: Experimental
Normalized name: WA-001 Experimental Soil Surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icotinib: 125mg, oral administration, three times per day.
Study: NCT01665417
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy Regimen 1：Pemetrexe 500 mg/m\^2 on Day 1, Cisplatin 75 mg/m\^2 on Day 1, 21 days/1 cycle, 2/4 cycles totally, until progression, withdrawal of consent, or unacceptable toxicity.
Study: NCT01665417
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy Regimen 2：Docetaxel 75 mg/m\^2 on Day 1, Cisplatin 75 mg/m\^2 on Day 1, 21 days/1 cycle, 2/4 cycles totally, until progression, withdrawal of consent, or unacceptable toxicity.
Study: NCT02198287
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00347711
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01433458
Drug: RLX030A
Approvals — FDA: no, EMA: no, PMDA: no
Description: RLX030 is administered as a continuous 24 hour infusion
Study: NCT02782663
Drug: ABT-494
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet: Oral
Study: NCT04356755
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: At day 0, patients will have placebo injections in their ischemic DU. Patients will be followed-up for 16 weeks
Study: NCT01787526
Drug: oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablets of 100mg iron over 8 weeks, total dose 10g
Study: NCT04081844
Drug: HCP1306
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10mg / Rosuvastatin 20mg (Rosuzet)
Study: NCT04081844
Drug: HGP0904
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 5mg(Norvasc)
Study: NCT04081844
Drug: HGP0608
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 100mg(Cozaar)
Study: NCT02802059
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial administration not later than 120h after birth. 14 ampoules a 1 ml are administered within a time of 3 weeks (1 ampoule per day within first week and 1 ampoule every second day within the following two weeks).~Subsequent re-administration after 6 and 12 months. 10 ampoules a 1 ml are administered within 10 days (1 ampoule per day).
Study: NCT01661400
Drug: Metronomic Cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00243230
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three tablets of placebo once daily for 48 weeks.
Study: NCT00243230
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two tablets of placebo once daily for 48 weeks.
Study: NCT02834676
Drug: Gelified Ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pain relief with chemonucleolysis by using gelified ethanol regard to age, sex, ASA score, and complications.
Study: NCT04183205
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo pills of the same size, color and taste as the active drug will be administered
Study: NCT01916122
Drug: Fluorestradiol (FES)
Normalized name: fluoroestradiol (18F)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03393364
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients receive ketorolac for pain control after outpatient urologic surgery
Study: NCT02187094
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01165021
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT00540553
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00540553
Drug: GSK971086
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02256865
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone is taken 3 times a day
Study: NCT02256865
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone gel is applied once a day
Study: NCT02256865
Drug: Placebo for hydrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for hydrocortisone
Study: NCT02256865
Drug: Placebo for testosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for testosterone
Study: NCT00990860
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After identifying the target artery of HCC, doxorubicin will be infused through the target artery of HCC patient with lipiodol emulsion (dependent on the tumor size)
Study: NCT04574284
Drug: TQB2450
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
Study: NCT04307576
Drug: Omitted Doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omission of IV Doxorubicin
Study: NCT04307576
Drug: 6-tioguanine+Standard Maintenance Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of p.o. 6-tioguanine to Standard Maintenance Therapy
Study: NCT03238092
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: testosterone gel daily during the late luteal phase.
Study: NCT03238092
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral estradiol during the late luteal phase.
Study: NCT01427569
Drug: IZN-6D4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard wound therapy plus twice weekly topical application of hydrogel containing botanical extracts.
Study: NCT01009801
Drug: doxorubicin-eluting beads
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive oral placebo or everolimus once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the MTD.
Study: NCT00408421
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00665496
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo
Study: NCT00165646
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: once daily orally for 4 weeks
Study: NCT03013322
Drug: Isotonic Saline
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00255684
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00294502
Drug: Gentamycin/citrate, Minocycline/EDTA
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03650452
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-935 placebo-matching tablets or mini-tablets.
Study: NCT03257930
Drug: ethanol injection
Normalized name: ethanol Injection
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: inject ethanol in cystic thyroid nodule and follow up until complete recovery
Study: NCT01013909
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of one dose daily by means of an metered dose
Study: NCT02044159
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone will be made up as a 10 mg/ml solution so the volume of added fluid will be very small (2 to 10 mls even for the initial dose of 2 mg/kg).
Study: NCT02713230
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL normal saline as single-injection
Study: NCT00162305
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, Oral, 0 mg, Once daily, 14 days.
Study: NCT02745223
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drops contains the same ingredients as PresbiDrops except for the active ingredients.
Study: NCT00861367
Drug: transurethral surgery with or without aspirin
Normalized name: aspirin / codeine phosphate Oral Tablet [Empirin with Codeine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: aspirin 100mg once a day, transurethral surgery with or without aspirin
Study: NCT03484923
Drug: PDR001
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of PDR001 administered every 4 weeks intravenously
Study: NCT03484923
Drug: LAG525
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of LAG525 administered every 4 weeks intravenously
Study: NCT03484923
Drug: INC280
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of INC280 administered twice daily orally
Study: NCT03484923
Drug: ACZ885
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of ACZ885 administered every 4 weeks subcutaneosuly
Study: NCT03484923
Drug: LEE011
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of LEE011 orally taken once daily on Days 1-21 of a 28-day cycle
Study: NCT01617681
Drug: VAL489
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 3mg/kg oral solution
Study: NCT03225924
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cycles of 21 days - 750 mg/m²
Study: NCT02917187
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo
Study: NCT03225924
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cycles of 21 days - 50mg/m²
Study: NCT02364206
Drug: LY2228820
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01462812
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT01571856
Drug: Zinc Sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: zinc sulfate solution, contains 20 mg. per 5 mL. dosage 2.5 mL. per day.
Study: NCT01533935
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo matching tiotropium + olodaterol
Study: NCT03071224
Drug: [18F] MNI-946
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will undergo PET imaging using \[18F\]MNI-946, a PET radioligand for imaging tau.
Study: NCT03136705
Drug: Nicotinamide
Normalized name: Nicotinamide
DrugBank: Nicotinamide (DB02701)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotinamide tablet
Study: NCT02146079
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomised to receive either semaglutide 0.5 mg, semaglutide 0.5 mg placebo, semaglutide 1.0 mg or semaglutide 1.0 mg placebo within each group. Treatment with active drug or placebo blinded within each dose level. After randomisation, the subjects will follow a fixed dose escalation. The maintenance dose of 0.5 mg will be reached after 4 weeks of 0.25 mg. The maintenance dose of 1.0 mg will be reached after 8 weeks (4 weeks) of 0.25 mg and 4 weeks of 0.5 mg). Once-weekly subcutaneous (s.c., under the skin) administration. Trial duration per subject is 18 to 21 weeks depending on the individual subject's schedule.
Study: NCT02855411
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, twice daily (BID) for 12 weeks, capsule
Study: NCT03587038
Drug: OKN 007
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg OKN-007/mL in a phosphate buffer
Study: NCT03965988
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01936285
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00080314
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, 0 mg, Once daily, 8 weeks.
Study: NCT03741699
Drug: Pre-treatment with rLH (Luveris 75 IU),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with 150 IU/day rLH (Luveris 75 IU), administered subcutaneously for 4 consecutive days prior to COS (Controlled ovarian stimulation)
Study: NCT01194557
Drug: Lumartem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presumptive treatment of malaria/fever
Study: NCT00471952
Drug: Maxalt 10mg MLT plus Caffeine 75mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: One migraine attack will be treated
Study: NCT00471952
Drug: Placebo + Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One migraine attack will be treated with double placebo
Study: NCT02538237
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: the mouthwash(ibuprofen 2% or placebo) Subgingival Irrigation of mouthwash with an insulin syringe 0.5 ml were rinsed.
Study: NCT02538237
Drug: Ibuprofen 2% mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00398541
Drug: losartan potassium (+) hydrochlorothiazide
Normalized name: hydrochlorothiazide / losartan potassium Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: losartan potassium (+) hydrochlorothiazide combination will be titrated upwards according to the following scheme: losartan potassium 50/hydrochlorothiazide 12.5 then losartan potassium 100/hydrochlorothiazide 12.5 then losartan potassium 100/hydrochlorothiazide 25
Study: NCT04123561
Drug: TLC599
Approvals — FDA: no, EMA: no, PMDA: no
Description: TLC599 is a proprietary (Bioseizer) lipid formulation containing DSP (active ingredient)
Study: NCT00653835
Drug: Ezetimibe + Simvastatin
Normalized name: ezetimibe / simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablets: ezetimibe 10 mg + simvastatin 20 mg once daily for 6 weeks
Study: NCT00653835
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral tablets: simvastatin 20 mg + ezetimibe placebo once daily for 6 weeks
Study: NCT00193440
Drug: CVP
Normalized name: CVP Manometer
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03237832
Drug: ARN-6039
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascending doses per Cohort
Study: NCT02053272
Drug: GWP42004
Approvals — FDA: no, EMA: no, PMDA: no
Description: The total dose administered within any 24-hour interval will be two capsules (typically 12 hours apart).
Study: NCT02053272
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The total dose administered within any 24-hour interval will be two capsules (typically 12 hours apart).
Study: NCT03632681
Drug: Intranasal Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal placebo manufactured to mimic smell of insulin
Study: NCT04181567
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT03521167
Drug: Tylenol Pill
Normalized name: Tylenol Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-operatively use. 1000 mg PO up to 1 hour before OR time Reduce to 650 mg PO if \<70kg Don't use if h/o liver disease or anticipated liver injury (right heart failure, pulmonary hypertension, etc leading to systemic venous congestion)
Study: NCT04314167
Drug: Lowering cholesterol concentrations by PCSK-9 inhibitor
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive the PCSK9-inhibitor Evolocumab as part of routine clinical management within the indication of this drug.
Study: NCT02891031
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg twice daily after meal for 6 weeks
Study: NCT03023982
Drug: Opioids
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard pain control with opioids
Study: NCT00468975
Drug: PF-610,355
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02191423
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered pre-fMRI assessment
Study: NCT00532948
Drug: capecitabine [Xeloda]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500mg/m2 po bid (starting dose)
Study: NCT02032537
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical water containing emollient (placebo) will be applied by the patient on the affected skin area whenever the pruritus starts including night time. The frequency of application will be regulated by individual patients and increased according to pruritus severity. The data on efficacy, duration of effect and frequency of application will be collected.during the study.
Study: NCT02345252
Drug: FTC/RPV/TDF Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally once daily
Study: NCT02345252
Drug: FTC/RPV/TDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200/25/300 mg FDC tablets administered orally once daily
Study: NCT02345252
Drug: FTC/RPV/TAF Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally once daily
Study: NCT02515864
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02812433
Drug: Ora-Blend
Normalized name: Ora-Blend Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ora-Blend, 2 mg/kg/dose per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life
Study: NCT03982771
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: -Cyclophosphamide: (oral) 300mg/m2 on Day 1, 8, 15, 22 every month for 9 months;
Study: NCT01184417
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 m l saline
Study: NCT02413125
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Most nasal irrigations use normal saline (0.9% sodium chloride), which approximates the physiological concentration of plasma in the blood. The saline solution is used to flush the nose of mucous and allergens.
Study: NCT01702363
Drug: GSK573719
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK573719 inhalation powder inhaled orally once daily for 52 weeks.
Study: NCT03252496
Drug: Intrathecal Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl 15 μg will be administered in the subarachnoid space
Study: NCT03252496
Drug: 250 mL Crystalloid over 60 minutes
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After 60 minutes of intrathecal injection, Ringer acetate 250 mL will be administered over 60 minutes
Study: NCT03252496
Drug: Intravenous Syntocinon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediately after delivery, syntocinon 10 IU will be added to the running crystalloid solution
Study: NCT02195791
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral) 1 tab once daily for 7 days
Study: NCT01293032
Drug: Aromatase Inhibition Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undergo hormonal therapy
Study: NCT00321984
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexlansoprazole placebo-matching capsules, orally, once daily for 4 weeks.
Study: NCT00911027
Drug: Contrast-enhanced ultrasound guided biopsy
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: One to two bolus (each 2.4mL) of SonoVue per patient in the optimization part~One to four bolus (each 2.4mL) of SonoVue per patient in the main part
Study: NCT02203331
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
Study: NCT02777073
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of generic placebo
Study: NCT01197144
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous, every other week for 4 weeks
Study: NCT00658372
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, oral, placebo, BID, 8 weeks with 2 week taper
Study: NCT05118958
Drug: KVD824 Prototype 1 modified-release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg modified-release tablet
Study: NCT05118958
Drug: KVD824 Immediate-Release Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg immediate-release capsule
Study: NCT05118958
Drug: Placebo to KVD824 Prototype 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to 300 mg KVD824 Prototype 1 modified-release tablet
Study: NCT05118958
Drug: KVD824 Prototype 3 modified-release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg modified-release tablet
Study: NCT00740779
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00450203
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dose banded as based on patient BSA. Oral dose given twice a day during each 21 day cycle of chemotherapy (6 cycles in total)
Study: NCT02344069
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 0.9% as a injection